Abstract
Asthma has reached epidemic proportions with approximately 200 million individuals affected worldwide. The disease is characterized by an oxidant / antioxidant imbalance in the lungs leading to activation of redox-sensitive transcription factors e.g. activator protein 1 (AP-1) and nuclear factor kappa B (NF-kappa B). We have previously described PNRI-299, a small molecule beta-strand mimetic template compound, as an inhibitor of the multifunctional AP endonuclease / redox factor 1 (Ref-1) [1]. PNRI-299 has demonstrable effects on the reduction of AP-1 driven transcription and beneficial pharmacological effects in a mouse asthma model. We now report the synthesis of this molecule and the effects of PNRI-299 on the expression of Leukotriene C4 (LTC4) synthase, a crucial enzyme for the formation of the cysteinyl leukotrienes.
Keywords: ap-1 transcriptional regulation, redox-sensitive transcription factors, activator protein 1
Letters in Drug Design & Discovery
Title: Chemogenomic Investigation of AP-1 Transcriptional Regulation of LTC4 Synthase Expression
Volume: 1 Issue: 3
Author(s): Tiana Chong, Michael McMillan, Jia Ling Teo, William R. Henderson Jr. and Michael Kahn
Affiliation:
Keywords: ap-1 transcriptional regulation, redox-sensitive transcription factors, activator protein 1
Abstract: Asthma has reached epidemic proportions with approximately 200 million individuals affected worldwide. The disease is characterized by an oxidant / antioxidant imbalance in the lungs leading to activation of redox-sensitive transcription factors e.g. activator protein 1 (AP-1) and nuclear factor kappa B (NF-kappa B). We have previously described PNRI-299, a small molecule beta-strand mimetic template compound, as an inhibitor of the multifunctional AP endonuclease / redox factor 1 (Ref-1) [1]. PNRI-299 has demonstrable effects on the reduction of AP-1 driven transcription and beneficial pharmacological effects in a mouse asthma model. We now report the synthesis of this molecule and the effects of PNRI-299 on the expression of Leukotriene C4 (LTC4) synthase, a crucial enzyme for the formation of the cysteinyl leukotrienes.
Export Options
About this article
Cite this article as:
Chong Tiana, McMillan Michael, Teo Ling Jia, Henderson Jr. R. William and Kahn Michael, Chemogenomic Investigation of AP-1 Transcriptional Regulation of LTC4 Synthase Expression, Letters in Drug Design & Discovery 2004; 1 (3) . https://dx.doi.org/10.2174/1570180043398920
DOI https://dx.doi.org/10.2174/1570180043398920 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prediction of Inhibition Activity of BET Bromodomain Inhibitors using Grid Search-Based Extreme Learning Machine and Molecular Docking
Letters in Drug Design & Discovery PIP3 Regulation as Promising Targeted Therapy of Mast-Cell-Mediated Diseases
Current Pharmaceutical Design Isolated Anosmia as a Presentation of COVID-19: An Experience in a Referral Hospital
Infectious Disorders - Drug Targets Highly Selective Phosphodiesterase 4 Inhibitors for the Treatment of Allergic Skin Diseases and Psoriasis
Inflammation & Allergy - Drug Targets (Discontinued) Cytokine Expression Profile in Aqueous Humor and Sera of Patients with Acute Anterior Uveitis
Current Molecular Medicine Nanotechnology-Based Drug Delivery Systems for Treatment of Hyperproliferative Skin Diseases - A Review
Current Nanoscience Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Current Drug Targets Meet Our Editor
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Recent Developments in the Synthesis of Bicyclic Condensed Pyrimidinones
Current Organic Chemistry Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Evaluation of Serum Level of Carnitine in Children with Acute Pyelonephritis (APN) Compared to Healthy Children
Reviews on Recent Clinical Trials Rapid Screening of Different Types of Antitumor Compound Groups from Traditional Chinese Medicine by Hollow Fiber Cell Fishing with High Performance Liquid Chromatography
Combinatorial Chemistry & High Throughput Screening Black Widow Spider (Latrodectus mactans) Antivenom in Clinical Practice
Current Pharmaceutical Biotechnology New Treatments for COPD in the Elderly
Current Pharmaceutical Design Current Anti-Inflammatory Therapies and the Potential of Secretory Phospholipase A2 Inhibitors in the Design of New Anti-Inflammatory Drugs: A Review of 2012 - 2018
Current Medicinal Chemistry Inhaled KMUP-1 Prevents Allergic Pulmonary Vascular Inflammation and Remodeling via NO and Suppressed MMP-9 and ICAM-1/VCAM-1
Inflammation & Allergy - Drug Targets (Discontinued) Adjuvant and Antigen Delivery Properties of Virosomes
Current Drug Delivery Self Managing Heart Failure in Remote Australia - Translating Concepts into Clinical Practice
Current Cardiology Reviews Allosteric Enhancers for A1 Adenosine Receptor
Mini-Reviews in Medicinal Chemistry